Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
Consensus recommendations for Trichophyton indotineae: A modified Delphi study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gupta Aditya K, Talukder Mesbah, Saunte Ditte Marie L, Hay Roderick James, Arabatzis Michael, Caplan Avrom S, Galili Eran, Haneke Eckart, Iorizzo Matilde, Kassem Riad, Khurana Ananta, Lipner Shari R, Lyakhovitsky Anna, Morrison Brian W, Piguet Vincent, Piraccini Bianca Maria, Rodríguez-Cerdeira Carmen, Shemer Avner, Starace Michela, Sundnes Olav, Tosti Antonella
Аннотация
BACKGROUND: Trichophyton indotineae (T. mentagrophytes genotype VIII) is spreading globally and is often terbinafine resistant. Guidance for diagnosis and treatment remains inconsistent.
METHODS: We performed a four-round modified Delphi study. A steering group developed a literature-informed, 42-item questionnaire on diagnosis and management. Consensus was predefined as ≥70% agreement.
RESULTS: Thirty-four experts were invited; 20 completed rounds 1 and 2 and 19 completed rounds 3 and 4. Consensus was achieved for 34/42 items (80.95%). The panel advised suspecting T. indotineae infection in patients with extensive or terbinafine-recalcitrant dermatophytosis, particularly those with a history of travel to or residence in endemic regions. For diagnosis, the panel recommended KOH direct microscopy and fungal culture for suspected dermatophyte infection, and PCR (polymerase chain reaction) with species-level discrimination or ITS sequencing for confirmation of T. indotineae. For resistance assessment, SQLE sequencing and antifungal susceptibility testing were preferred where available, particularly after treatment failure. For treating superficial fungal infections caused by T. indotineae, experts recommended oral itraconazole therapy (100-200 mg/day for 6-8 weeks, or longer as clinically indicated), with luliconazole 1% cream as the preferred adjunctive topical option. Oral posaconazole (300 mg/day for 4-12 weeks) can be considered as the salvage therapy following itraconazole failure, keeping in mind antifungal stewardship.
CONCLUSIONS: These consensus statements provide practical interim recommendations. Randomized controlled trials are needed to validate outcomes and optimize regimens.
METHODS: We performed a four-round modified Delphi study. A steering group developed a literature-informed, 42-item questionnaire on diagnosis and management. Consensus was predefined as ≥70% agreement.
RESULTS: Thirty-four experts were invited; 20 completed rounds 1 and 2 and 19 completed rounds 3 and 4. Consensus was achieved for 34/42 items (80.95%). The panel advised suspecting T. indotineae infection in patients with extensive or terbinafine-recalcitrant dermatophytosis, particularly those with a history of travel to or residence in endemic regions. For diagnosis, the panel recommended KOH direct microscopy and fungal culture for suspected dermatophyte infection, and PCR (polymerase chain reaction) with species-level discrimination or ITS sequencing for confirmation of T. indotineae. For resistance assessment, SQLE sequencing and antifungal susceptibility testing were preferred where available, particularly after treatment failure. For treating superficial fungal infections caused by T. indotineae, experts recommended oral itraconazole therapy (100-200 mg/day for 6-8 weeks, or longer as clinically indicated), with luliconazole 1% cream as the preferred adjunctive topical option. Oral posaconazole (300 mg/day for 4-12 weeks) can be considered as the salvage therapy following itraconazole failure, keeping in mind antifungal stewardship.
CONCLUSIONS: These consensus statements provide practical interim recommendations. Randomized controlled trials are needed to validate outcomes and optimize regimens.